Emerging trends in hepatocellular carcinoma incidence and mortality.
about
Diabetes mellitus and metformin in hepatocellular carcinomaAn orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.Hepatocellular carcinoma in patients with non-alcoholic fatty liver diseaseCancer and liver cirrhosis: implications on prognosis and managementBurden of hepatocellular carcinoma among hispanics in South Texas: a systematic review.Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.High TGF-β1 expression predicts poor disease prognosis in hepatocellular carcinoma patientsReview of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis3'UTR polymorphisms of carbonic anhydrase IX determine the miR-34a targeting efficiency and prognosis of hepatocellular carcinoma.Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair.Estradiol and Estrogen Receptor Agonists Oppose Oncogenic Actions of Leptin in HepG2 CellsDisparities in care for patients with curable hepatocellular carcinomaPrognostic significance of synergistic hexokinase-2 and beta2-adrenergic receptor expression in human hepatocelluar carcinoma after curative resectionElevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma.Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice.Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular CarcinomaCorona Enhancement and Mosaic Architecture for Prognosis and Selection Between of Liver Resection Versus Transcatheter Arterial Chemoembolization in Single Hepatocellular Carcinomas >5 cm Without Extrahepatic Metastases: An Imaging-Based RetrospectiProtein kinase CK2α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma.Argonaute 2 promotes angiogenesis via the PTEN/VEGF signaling pathway in human hepatocellular carcinoma.Development of a radiofrequency ablation platform in a clinically relevant murine model of hepatocellular cancer.Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.Computed tomography texture analysis to facilitate therapeutic decision making in hepatocellular carcinoma.Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012.NEK2 serves as a prognostic biomarker for hepatocellular carcinoma.miR-34a regulates HDAC1 expression to affect the proliferation and apoptosis of hepatocellular carcinoma.Needle track seeding after radiofrequency ablation for hepatocellular carcinoma: prevalence, impact, and management challenge.Improved survival of patients with hepatocellular carcinoma and disparities by age, race, and socioeconomic status by decade, 1983-2012.Vitexin suppresses autophagy to induce apoptosis in hepatocellular carcinoma via activation of the JNK signaling pathway.Chemical inhibition reveals differential requirements of signaling pathways in krasV12- and Myc-induced liver tumors in transgenic zebrafish.Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.The evolving epidemiology of hepatocellular carcinoma: a global perspective.Distinct hepatitis B virus integration patterns in hepatocellular carcinoma and adjacent normal liver tissue.Diagnostic Value of the Combination of Golgi Protein 73 and Alpha-Fetoprotein in Hepatocellular Carcinoma: A Meta-Analysis.Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient.A national survey of the provision of ultrasound surveillance for the detection of hepatocellular carcinomaPattern of distant extrahepatic metastases in primary liver cancer: a SEER based studyHealth and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model.Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma.
P2860
Q26741205-C1C50142-7E24-43D1-869D-1DC7D579260AQ27310334-B17BA095-0AD2-478F-8BBE-EEA9811F699EQ28066100-92A94B7F-AC26-42F2-BA3A-4DE955534648Q28068579-340AA667-B74F-4C9D-A5BA-EB4BCF53EEF6Q30234676-C1FF4B19-72B1-468F-925C-C9AD9680C6D7Q33577628-3F5D3A04-47C0-4EEF-AD6F-8E373FE0062DQ33652164-60FF4E77-B500-4F9A-BEAD-8973EA0802C7Q33798379-4C8179E4-239D-4FE0-AF17-0DA75AC751E7Q33851416-216667B2-8490-4D1C-962B-592A4B0D6B77Q33860879-11C49D34-4780-403C-BA91-619D9B08C7FDQ33914180-51D1CE1D-B718-414A-AFC3-5253522CABEEQ35890736-245D4A23-D4F4-4B1B-A0DC-18852D075528Q35959401-82614102-45A0-484D-920B-6F789BBCF3D5Q36019636-665635FA-EF94-44F4-AB7F-167913C55198Q36038720-BA3421A8-C064-4B8A-8645-12379F82C568Q36109796-E1ED869F-4ACD-4C0E-B8E4-A349E89BE21BQ36199751-0FC8CFD6-39CC-4ED2-9A68-BEDDA7605386Q36244298-B303A7B7-5104-4FA4-8DF9-97927F708E35Q36478152-2B65EC69-1C41-4CD4-A13D-FE0FAF10619DQ36544222-D28A2B6C-23B7-4161-8467-BAC986A98634Q36746133-7E38FDD6-177F-4BC4-9A33-EAA17AF22C05Q36844302-4327D6F4-D9EF-481C-A63E-E154359ACEAEQ36939981-EC922BCD-1CCC-4E52-9DFA-52DC1521715DQ37022447-5A0A1515-B274-4C14-9EA4-7C26E1B50FCAQ37338966-313983AC-8B70-4A21-BCDA-23991C528439Q37588101-850EECAA-0CF3-4EFD-8D9D-B149E72E0CDCQ37596868-3AEF4F6D-28E2-41BF-B916-B42637CCAE39Q37608627-01E3D2AC-5B55-4274-AC80-93017EC889B1Q37644945-15A4A134-04F5-43BF-94DD-86040721DD02Q37708976-BA9B9600-D579-4F3B-8E3E-AC499BE4258BQ37738003-F80DA118-155F-4CA6-9F81-0247CA0246CCQ38366584-A75097E3-5F58-4E98-9699-49087FF6AB89Q38397998-357ABBDA-7809-42AB-B49E-F76A0A223B3FQ38439272-459C9B2D-71D8-468D-8843-B3179BFBAF33Q38600597-2D5BC843-D455-4866-99A4-F5B88540A3FDQ38604896-32F8C8B6-B452-4DBE-8291-97254BBB3CA2Q38608539-39FB204F-5298-40CA-9646-D3E56909DD20Q38640503-62DC64CC-E048-4AF8-B752-19730AAB5100Q38642356-27E58963-B8A0-4115-ADFF-BDE45214A639Q38719022-00F3BECC-B8DD-4B77-A5EF-78F4A9061E1D
P2860
Emerging trends in hepatocellular carcinoma incidence and mortality.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Emerging trends in hepatocellular carcinoma incidence and mortality
@nl
Emerging trends in hepatocellular carcinoma incidence and mortality.
@ast
Emerging trends in hepatocellular carcinoma incidence and mortality.
@en
type
label
Emerging trends in hepatocellular carcinoma incidence and mortality
@nl
Emerging trends in hepatocellular carcinoma incidence and mortality.
@ast
Emerging trends in hepatocellular carcinoma incidence and mortality.
@en
prefLabel
Emerging trends in hepatocellular carcinoma incidence and mortality
@nl
Emerging trends in hepatocellular carcinoma incidence and mortality.
@ast
Emerging trends in hepatocellular carcinoma incidence and mortality.
@en
P2093
P2860
P3181
P356
P1433
P1476
Emerging trends in hepatocellular carcinoma incidence and mortality.
@en
P2093
Basile Njei
Joseph K Lim
P2860
P304
P3181
P356
10.1002/HEP.27388
P407
P50
P577
2014-11-24T00:00:00Z